Comparison of effects of ivabradine versus carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Yue Chun, Li ^a   Teng, Zhang ^a   Na Dan, Zhou ^a   Li Sha, Ge ^a   Qin, Luo ^a   Xue Qiang, Guan ^a   Jia Feng, Lin ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; INTERLEUKIN 6; IVABRADINE; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NORADRENALIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COXSACKIE VIRUS B3; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REGULATION; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; HEART RATE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VIRUS MYOCARDITIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; APOPTOSIS; BENZAZEPINES; CARBAZOLES; COXSACKIEVIRUS INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; HEART; HEART RATE; MALE; MICE; MYOCARDIAL CONTRACTION; MYOCARDITIS; MYOCARDIUM; OXIDATIVE STRESS; PROPANOLAMINES;

COXSACKIEVIRUS; MURINAE; MUS;

EID: 84863004116     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039394     Document Type: Article

References (43)

1. Feldman AM, McNamara D, (2000) Myocarditis. N Engl J Med 343: 1388-1398.
2. Pauschinger M, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, et al. (1999) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99: 889-895.
3. Opasich C, Rapezzi C, Lucci D, Gorini M, Pozzar F, et al. (2001) Italian Network on Congestive Heart Failure (IN-CHF) investigators. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol 88: 382-7.
4. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, et al. (2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26: 2259-68.
5. Heusch G, (2008) Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153: 1589-1610.
6. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, et al. (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56: 1973-83.
7. Yue-chun L, Li-sha G, Jiang-hua R, Peng-Lin Y, Jia-Feng L, et al. (2008) Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol 51: 92-98.
8. Yue-chun L, Li-sha G, Peng-Lin Y, Ji-Fei T, Jia-Feng L, et al. (2010) Carvedilol decreases elevated oxidative stress in murine coxsackievirus-induced acute viral myocarditis. Eur J Pharmacol 640: 112-116.
9. Yue-chun L, Li-sha G, Xue-qiang G, Jia-Feng L, (2012) The mechanism of carvedilol in experimental viral myocarditis. Curr Pharm Des 18: 1620-1624.
10. Nishio R, Shioi T, Sasayama S, Matsumori A, (2003) Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardilol 41: 340-345.
11. Bois P, Bescond J, Renaudon B, Lenfant J, (1996) Mode of action of bradycardic agent, S16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 118: 1051-7.
12. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, et al. (2004) Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109: 1674-9.
13. Couvreur N, Tissier R, Pons S, Chetboul V, Gouni V, et al. (2010) Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J 31: 1529-37.
14. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, et al. (2011) Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 300: H366-H373.
15. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, et al. (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875-85.
16. Tardif JC, O'Meara E, Komajda M, Böhm M, Borer JS, et al. (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32: 2507-15.
17. Heusch G, (2008) Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol 155: 970-1.
18. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, et al. (2008) Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 29: 2265-75.
19. Custodis F, Baumhakel M, Schlimmer N, List F, Gensch C, et al. (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117: 2377-87.
20. Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, et al. (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117: 234-42.
21. Schirmer SH, Degen A, Baumhäkel M, Custodis F, Schuh L, et al. (2011) Heart-rate reduction by If-channel inhibition with ivabradine restores collatera lartery growth in hypercholesterolemic atherosclerosis. Eur Heart J doi:10.1093/eurheartj/ehr255. [Epub ahead of print].
22. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, et al. (2008) Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 154: 749-757.
23. Shioi T, Matsumori A, Sasayama S, (1996) Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 94: 2930-7.
24. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y, (1997) Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus B3. J Pathol 183: 105-8.
25. Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, et al. (1998) Myocarditis induced by targeted expression of the MCP-1gene in murine cardiac muscle. Am J Pathol 152: 101-11.
26. Tanaka T, Kanda T, McManus BM, Kanai H, Akiyama H, et al. (2001) Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-α. J Mol Cell Cardiol 33: 1627-35.
27. Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I, et al. (2000) Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol 36: 1288-94.
28. Dawson J, Miltz W, Mir AK, Wiessner C, (2003) Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 7: 35-48.
29. Kaya Z, Leib C, Werfel S, Göser S, Öttl R, et al. (2011) Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis. Cardiovasc Res 91: 116-23.
30. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, et al. (2004) Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 25: 363-370.
31. Kapadia SR, (1999) Cytokines and heart failure. Cardiol Rev 7: 196-206.
32. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 311: 819-23.
33. Harris TJ, Waltman TJ, Carter SM, Maisel AS, (1995) Effect of prolonged catecholamine infusion on immunoregulatory function: Implications in congestive heart failure. J Am Coll Cardiol 26: 102-9.
34. Müller-Werdan U, Jacoby J, Loppnow H, Werdan K, (1999) Noradrenaline stimulates cardiomyocytes to produce interleukin-6, indicative of a proinflammatory action, which is suppressed by carvedilol. Eur Heart J 20 (Suppl): P1721.
35. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF, (1996) Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin-10 production during human endotoxemia. J Clin Invest 97: 713-9.
36. Kröller-Schön S, Schulz E, Wenzel P, Kleschyov AL, Hortmann M, et al. (2011) Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction andoxidative stress. Basic Res Cardiol 106: 1147-1158.
37. Feuerstein GZ, Shusterman NH, Ruffolo RR, (1997) Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression congestive heart failure. Drugs Today 33: 453-473.
38. Pauschinger M, Rutschow S, Chandrasekharan K, Westermann D, Weitz A, et al. (2005) Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 7: 444-452.
39. Saraste A, Arola A, Vuorinen T, Kytö V, Kallajoki M, et al. (2003) Cardiomyocyte apoptosis in experimental coxsackievirus B3 myocarditis. Cardiovasc Pathol 12: 255-262.
40. Colston JT, Chandrasekar B, Freeman GL, (1998) Expression of apoptosis-related proteins in experimental coxsackievirus myocarditis. Cardiovasc Res 38: 158-168.
41. Zheng W, Brown MD, Brock TA, Bjercke RJ, Tomanek RJ, (1999) Bradycardia-induced coronary angiogenesisis dependent on vascular endothelial growth factor. Circ Res 85: 192-198.
42. Wright AJ, Hudlicka O, (1981) Capillary growth and changes in heart performance induced by chronic bradycardial pacing in the rabbit. Circ Res 49: 469-478.
43. Ulu N, Henning RH, Goris M, Schoemaker RG, van Gilst WH, (2009) Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure. J Cardiovasc Pharmacol 53: 9-17.